Evrysdi

Chemical Namerisdiplam
Dosage FormSolution (oral; 60 mg, 0.75 mg/mL)
Drug ClassMiscellaneous
SystemNervous
CompanyGenentech Inc.
Approval Year2020

Indication

  • For the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Evrysdi (risdiplam) Prescribing Information 2020Genentech Inc., South San Francisco, CA